Collegium Pharmaceutical (COLL) Receivables - Other (2024 - 2026)

Collegium Pharmaceutical has reported Receivables - Other for 3 years, with the latest figure at $19.8 million in Q2 2026.

• On a quarterly basis, Receivables - Other changed N/A year-over-year to $19.8 million in Q2 2026; TTM through Jun 2026 was $19.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $19.8 million, down 20.6% from the prior year.
• Receivables - Other was $19.8 million for Q2 2026 at Collegium Pharmaceutical, roughly flat from $19.8 million in the prior quarter.
• The five-year high for Receivables - Other was $25.0 million in Q4 2024, with the low at $19.8 million in Q4 2025.
• Average Receivables - Other over 3 years is $21.1 million, with a median of $19.8 million recorded in 2025.
• The largest YoY upside for Receivables - Other was 20.6% in 2025 against a maximum downside of 20.6% in 2025.
• Over 3 years, Receivables - Other stood at $25.0 million in 2024, then dropped by 20.6% to $19.8 million in 2025, then changed by 0.0% to $19.8 million in 2026.
• The last three Receivables - Other figures came in at $19.8 million (Q2 2026), $19.8 million (Q1 2026), and $19.8 million (Q4 2025), per Business Quant data.